1. Mazzucchelli, Renata, and Scott K. Durum. "Interleukin-7 receptor expression: intelligent design." Nature Reviews Immunology 7.2 (2007): 144-154.
2. Fry, Terry J., and Crystal L. Mackall. "Interleukin-7: from bench to clinic." Blood, The Journal of the American Society of Hematology 99.11 (2002): 3892-3904.
3. Ponchel, Frederique, et al. "Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia." Arthritis Res Ther 7.1 (2004): R80.
4. Seddiki, N. Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. "Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells." J Exp Med 203 (2006): 1693-1700.
Visit our Scientific Publication section for more information on NT-I7 for Oncology.
NIT is collaborating with major cancer centers and universities in the U.S. and South Korea for our clinical trials with NT-I7. To learn about our on-going cancer clinical trials, please click Here .
1. Maintaining homeostasis
- Supports thymopoeisis
- Boosts Tnaive cell numbers
- Maintains stable pools of diverse resting peripheral T cells, including Tscm
2. Initial Immune Response
- Boosts Tnaive cell numbers andbroadens TCR repertoire diversity
- Increases sensitivity to weaker antigens
- Synergizes with TCR signaling
3. Adaptive Immune Response
- Promotes Tmemory differentiation and turnover
- Limits T cell exhaustion
- Sustains immune response to chronic antigen stimulation
Visit our Scientific Publication section for more information on NT-I7 for immunological disorders.
NIT is collaborating with major cancer centers and universities in the U.S. and South Korea for our clinical trials with NT-I7. To learn about our clinical trials for immunological disorders, please click Here .